Log in

Shire Stock Price, News & Analysis (NASDAQ:SHPG)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$179.20
MA: $179.20
$179.20
52-Week Range N/A
VolumeN/A
Average Volume2.21 million shs
Market Capitalization$54.71 billion
P/E Ratio11.83
Dividend Yield0.19%
Beta0.87
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.16 billion
Book Value$119.43 per share

Profitability

Net Income$4.27 billion

Miscellaneous

EmployeesN/A
Market Cap$54.71 billion
Next Earnings DateN/A
OptionableOptionable

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.


Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) issued its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping the consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. Shire's revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.63 EPS. View Shire's Earnings History.

What price target have analysts set for SHPG?

5 equities research analysts have issued 1-year price targets for Shire's shares. Their predictions range from $195.00 to $222.00. On average, they expect Shire's stock price to reach $208.50 in the next year. View Analyst Price Targets for Shire.

What is the consensus analysts' recommendation for Shire?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.

Has Shire been receiving favorable news coverage?

Headlines about SHPG stock have trended negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Shire earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Shire.

Who are some of Shire's key competitors?

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Celgene (CELG), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Starbucks (SBUX), Johnson & Johnson (JNJ), Pfizer (PFE) and Exxon Mobil (XOM).

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)

How big of a company is Shire?

Shire has a market capitalization of $0.00 and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. View Additional Information About Shire.

What is Shire's official website?

The official website for Shire is http://www.shire.com/.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (NASDAQ SHPG)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,057 (Thanks for Voting!)
Underperform Votes:  592 (Thanks for Voting!)
Total Votes:  1,649
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel